Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. August 2025 16:15 ET | Quelle: Jabez Biosciences, Inc.

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

Jabez Biosciences Announces Opening of Second Clinical Site in Phase 1 study in Solid Tumors and NHL
16. Oktober 2020 05:25 ET | Quelle: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

-- ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...
22. November 2019 01:30 ET | Quelle: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical...
02. Dezember 2018 12:00 ET | Quelle: ASLAN Pharmaceuticals Limited

New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia

SINGAPORE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...